The role of microrna-346 in prostate cancer progression: Clinical significance and biomarker potential

Lei Wang, Yanqing Wang, Tianrui Li, Zhengwei Wang, Xiaoqiang Liu, G. ChenJournal of Medical Biochemistry 2025 · DOI

TL;DR

This study investigates the role of microRNA-346 (miR-346) in prostate cancer (PCa) progression, finding its expression is significantly lower in PCa tissues compared to benign prostatic hyperplasia (BPH) and healthy controls. Crucially, serum miR-346 levels increase during the transition to hormone-resistant PCa, suggesting its potential as a non-invasive biomarker for monitoring disease progression.

What Problem Does This Paper Address?

Prostate cancer (PCa) is a major health concern, and its diagnosis and monitoring present challenges. Current PCa biomarkers, like prostate-specific antigen (PSA), have limitations in specificity and sensitivity. Furthermore, tracking the progression of PCa, particularly the difficult transition from hormone-sensitive to castration-resistant PCa (CRPC), is crucial for effective treatment but lacks ideal monitoring tools. The paper addresses the need for more sensitive, specific, and non-invasive biomarkers to aid in PCa diagnosis, risk assessment, and monitoring of disease progression, especially during therapeutic transitions.

Methods

The researchers employed quantitative real-time polymerase chain reaction (qRT-PCR) to measure the relative expression of miR-346 in both tissue and serum samples. Statistical analysis was performed using GraphPad Prism, including t-tests, ANOVA, and Spearman bivariate rank correlation to assess expression changes and their relationships with clinical and pathological features. They also conducted prognostic follow-up for patients to observe long-term outcomes.

Datasets

The study utilized clinical data and biological samples from a cohort of patients treated at Tengzhou Central People's Hospital between January 2017 and December 2023. The patient groups included:

  • Newly diagnosed PCa patients (n=128)
  • Benign prostatic hyperplasia (BPH) patients (n=130)
  • Hormone-sensitive PCa (HSPC) patients (n=120)
  • Castration-resistant PCa (CRPC) patients (n=116)
  • Healthy male controls (n=150)

Tissue and preoperative serum samples were collected from these individuals.

Key Insights and Ideas

  • Dual Role of miR-346: The study suggests miR-346 may have a dual role in PCa, acting as a tumor suppressor in early stages (lower expression in PCa vs. BPH/healthy) but potentially as an oncogene in later stages (increasing expression in CRPC).
  • Serum miR-346 as a Biomarker: The increasing trend of serum miR-346 during the transition to hormone resistance is a significant finding, highlighting its potential as a non-invasive marker for monitoring disease progression.
  • Correlation with Clinical Parameters: miR-346 expression in PCa tissues and serum was negatively correlated with key indicators like total PSA (tPSA), Prostate Health Index (PHI), clinical stage, and Gleason score, reinforcing its association with disease severity.
  • Hormone Resistance Transition: The study observed that higher serum miR-346 levels in CRPC patients were associated with shorter conversion times from hormone sensitivity to castration resistance and shorter life expectancy.

Key Results

  • miR-346 expression was significantly lower in PCa tissues compared to BPH tissues and healthy populations (P<0.001).
  • Serum miR-346 expression was significantly lower in PCa patients than in CRPC patients (P<0.001).
  • Serum miR-346 expression was positively correlated with tPSA and ALP in HSPC and CRPC patients.
  • Serum miR-346 in CRPC patients was negatively correlated with time to transformation (r=0.6575) and survival (r=0.5699) (P<0.001).
  • miR-346 was negatively correlated with tPSA, PHI, clinical stage, and Gleason score in PCa tissue/serum (P<0.001).

Limitations and Future Work

The authors acknowledge several limitations:

  • Causality Unproven: While strong correlations were found between miR-346 and clinical parameters, the causal relationship remains unproven.
  • Lack of Longitudinal Data: The study did not track the same patients longitudinally from initial diagnosis through to CRPC, limiting the ability to analyze the entire progression process.
  • Mechanistic Understanding: Further functional studies, such as CRISPR-Cas9-mediated miR-346 knockdown, are needed to elucidate its precise mechanistic role in PCa pathogenesis.
  • Further Validation: More extensive validation of miR-346's diagnostic efficacy compared to established markers like PCA3 is recommended.

Future work should focus on investigating the cell signal transduction pathways and molecular biological mechanisms underlying miR-346's role in PCa progression.

Summary updated

Abstract

Serum miR-346 expression in hormone resistance transition in PCa is gradually increasing, making it a potential biomarker for monitoring PCa progression.
BibTeX
@article{wang2025role,
  author = {Lei Wang and Yanqing Wang and Tianrui Li and Zhengwei Wang and Xiaoqiang Liu and G. Chen},
  title = {{The role of microrna-346 in prostate cancer progression: Clinical significance and biomarker potential}},
  journal = {Journal of Medical Biochemistry},
  year = {2025},
  doi = {10.5937/jomb0-58279},
}
Figure